Depression in patients with heart disease: The case for more trials

Future Cardiology

Volumn 6, Issue 4, 2010, Pages 547-556

  Liu, Stanley S ^a   Ziegelstein, Roy C ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

antidepressant treatment; cardiovascular disease; depression; mortality; randomized controlled trial

Indexed keywords

CHOLESTEROL; CITALOPRAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO;

AEROBIC EXERCISE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; HEALTH EDUCATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRESS MANAGEMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEPRESSIVE DISORDER; HEART DISEASES;

CLINICAL TRIALS AS TOPIC; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; HEART DISEASES; HUMANS;

EID: 77954486078     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.18     Document Type: Review

References (58)

1. Thombs BD, Bass EB, Ford DE et al.: Prevalence of depression in survivors of acute myocardial infarction. J. Gen. Intern. Med. 21, 30-38 (2006).
2. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ: Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J. Am. Coll. Cardiol. 48, 1527-1537 (2006).
3. Frasure-Smith N, Lespérance F: Depression and cardiac risk: present status and future directions. Heart 96(3), 173-176 (2010).
4. Carney RM, Freedland KE: Depression and heart rate variability in patients with coronary heart disease. Cleve. Clin. J. Med. 76(Suppl. 2), S13-S17 (2009).
5. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC: Platelet activation in depression and effects of sertraline treatment: an open-label study. Am. J. Psychiatry 157, 1006-1008 (2000).
6. Serebruany VL, Glassman AH, Malinin AI et al.: Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul. Fibrinolysis 14, 563-567 (2003).
7. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgreen LA: Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143, 993-997 (1986).
8. Laje RP, Berman JA, Glassman AH: Depression and nicotine: preclinical and clinical evidence for common mechanisms. Curr. Psychiatry Rep. 3, 470-474 (2001).
9. Paperwalla KN, Levin TT, Weiner J, Saravay SM: Smoking and depression. Med. Clin. North Am. 88, 1483-1494 (2004).
10. Kamphuis MH, Geerlings MI, Tijhuis MAR et al.: Physical inactivity, depression, and risk of cardiovascular mortality. Med. Sci. Sports Exerc. 39, 1693-1699 (2007).
11. DiMatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160, 2101-2107 (2000).
12. Gehi A, Haas D, Pipkin S, Whooley MA: Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch. Intern. Med. 165, 2508-2513 (2005). (Pubitemid 41720013)
13. Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N. Engl. J. Med. 303, 1038-1041 (1980).
14. Horwitz RI, Viscoli CM, Berkman L: Treatment adherence and risk of death after a myocardial infarction. Lancet 336, 542-545 (1990).
15. Irvine J, Baker B, Smith J: Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom. Med. 61, 566-575 (1999).
16. Granger BB, Swedberg K, Ekman I: Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366, 2005-2011 (2005).
17. Glassman AH, O'Connor CM, Califf RM et al.; Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288, 701-709 (2002).
18. Honig A, Kuyper AM, Schene AH et al.; MIND-IT Investigators: Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom. Med. 69, 606-613 (2007).
19. Berkman LF, Blumenthal J, Burg M et al.; Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD): Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA 289, 3106-3116 (2003).
20. Van Melle JP, De Jonge P, Honig A; MIND-IT Investigators: Effects of antidepressant treatment following myocardial infarction. Br. J. Psychiatry 190, 460-466 (2007).
21. Lichtman JH, Bigger Jr. JT, Blumenthal JA et al.; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association: Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118, 1768-1775 (2008).
22. Pozuelo L, Tesar G, Zhang J, Penn M, Franco K, Jiang W: Depression and heart disease: what do we know, and where are we headed? Cleve. Clin. J. Med. 76, 59-70 (2009).
23. Glassman AH, Bigger Jr. JT, Gaffney M: Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch. Gen. Psychiatry 66, 1022-1029 (2009).
24. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Roose SP, Sheps DS; International Consensus Group on Depression and Anxiety: Consensus statement on depression, anxiety, and cardiovascular disease. J. Clin. Psychiatry 62(Suppl. 8), 24-27 (2001).
25. US Preventive Services Task Force: Screening for depression in adults: US preventive services task force recommendation statement. Ann. Intern. Med. 151, 784-792 (2009).
26. Wu SY, Nemesure B, Hennis A, Schachat AP, Hyman L, Leske MC; Barbados Eye Studies Group: Open-angle glaucoma and mortality: the Barbados Eye Studies. Arch. Ophthalmol. 126, 365-370 (2008).
27. Lee AJ, Wang JJ, Kifley A, Mitchell P: Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology 113, 1069-1076 (2006). (Pubitemid 43947257)
28. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P: Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br. J. Ophthalmol. 92, 509-512 (2008).
29. Rumsfeld JS, Ho PM: Depression and cardiovascular disease: a call for recognition. Circulation 111, 250-253 (2005).
30. Yarnall KS, Pollak KI, Østbye T, Krause KM, Michener JL: Primary care: is there enough time for prevention? Am. J. Public Health 93, 635-641 (2003).
31. Schneiderman N, Saab PG, Catellier DJ et al.; ENRICHD Investigators: Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. Psychosom. Med. 66, 475-483 (2004).
32. Freedland KE, Carney RM, Lustman PJ, Rich MW, Jaffe AS: Major depression in coronary artery disease patients with vs. without a prior history of depression. Psychosom. Med. 54, 416-421 (1992).
33. Grace SL, Abbey SE, Kapral MK, Fang J, Nolan RP, Stewart DE: Effect of depression on five-year mortality after an acute coronary syndrome. Am. J. Cardiol. 96, 1179-1185 (2005).
34. De Jonge P, Van Der Brink RH, Spijkerman TA, Ormel J: Only incident depressive episodes after myocardial infarction are associated with new cardiovascular events. J. Am. Coll. Cardiol. 48, 2204-2208 (2006).
35. Saab PG, Bang H, Williams RB et al.; ENRICHD Investigators: The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. J. Psychosom. Res. 67, 45-56 (2009).
36. Rollman BL, Belnap BH, LeMenager MS et al.: Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA 302, 2095-2103 (2009).
37. Fournier JC, DeRubeis RJ, Hollon SD et al.: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303, 47-53 (2010).
38. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5, E45 (2008).
39. Holme I: An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 82, 1916-1924 (1990).
40. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 91, 2274-2282 (1995).
41. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97, 946-952 (1998).
42. Cohen HW, Gibson G, Alderman MH: Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am. J. Med. 108, 2-8 (2000).
43. Glassman AH, Roose SP, Bigger Jr. JT: The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 269, 2673-2675 (1993).
44. Roose SP, Laghrissi-Thode F, Kennedy JS et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279, 287-291 (1998).
45. Thombs BD, De Jonge P, Coyne JC et al.: Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 300, 2161-2171 (2008).
46. Ioannidis JP: Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch. Intern. Med. 169, 1737-1739 (2009).
47. Whang W, Kubzansky LD, Kawachi I et al.: Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J. Am. Coll. Cardiol. 53, 950-958 (2009).
48. Krantz DS, Whittaker KS, Francis JL et al.: Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 95, 1901-1906 (2009).
49. Smoller JW, Allison M, Cochrane BB et al.: Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch. Intern. Med. 169, 2128-2139 (2009).
50. Frasure-Smith N, Lespérance F, Prince RH et al.: Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet 350, 473-479 (1997).
51. Lespérance F, Frasure-Smith N, Koszycki D et al.; CREATE Investigators: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 297, 367-379 (2007).
52. Blumenthal JA, Babyak MA, Doraiswamy PM et al.: Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom. Med. 69, 587-596 (2007).
53. Blumenthal JA, Sherwood A, Babyak MA et al.: Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA 293, 1626-1634 (2005).
54. De Jonge P, Honig A, Van Melle JP et al.; MIND-IT Investigators: Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am. J. Psychiatry 164, 1371-1378 (2007).
55. Carney RM, Freedland KE: Treatment-resistant depression and mortality after acute coronary syndrome. Am. J. Psychiatry 166, 410-417 (2009).
56. Glassman AH, Bigger Jr. JT, Gaffney M: Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Seven-year follow-up of SADHART participants. Arch. Gen. Psychiatry 66, 1022-1029 (2009).
57. Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM: Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am. Heart J. 150, 54-78 (2005).
58. Remarks by the President at the Summit of the Americas Opening Ceremony, 17 April 2009 www.whitehouse.gov/the-press-office/ Remarks-by-the-President-at- the-Summit-of-the-Americas-Opening-Ceremony Accessed 24 January 2010